Loading...
XSHE
002873
Market cap319mUSD
Jun 16, Last price  
9.73CNY
1D
-0.71%
1Q
-2.11%
IPO
11.18%
Name

Guiyang Xintian Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
28.31
P/S
2.40
EPS
0.34
Div Yield, %
0.72%
Shrs. gr., 5y
1.28%
Rev. gr., 5y
6.56%
Revenues
954m
-12.29%
330,088,865406,126,853454,125,518521,910,598633,186,158681,714,129694,259,400773,337,464750,946,390969,844,4721,087,673,294953,981,876
Net income
81m
-27.48%
26,392,57015,094,99233,123,98142,010,47157,069,48466,116,84470,975,49671,422,16572,546,44599,475,885111,518,64480,871,062
CFO
78m
+2.59%
21,407,33113,879,02237,304,16140,731,17161,343,77862,060,03547,592,57933,728,459175,767,527124,300,30475,818,17477,782,320
Dividend
Jun 25, 20240.07 CNY/sh
Earnings
Aug 27, 2025

Profile

Guiyang Xintian Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of Chinese medicines for various diseases in China. The company offers formulation products, which include hard capsules, gels, mixtures, granules, and tablets. Its products are used for the treatment of antitumor, gynecological, urinary, breast thyroid, blood, heat, oral, anti-cold, and cardiovascular diseases. The company was founded in 1995 and is based in Guiyang, China.
URL
http://www.gyxtyy.com/
IPO date
May 19, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
953,982
-12.29%
1,087,673
12.15%
Cost of revenue
686,291
846,417
Unusual Expense (Income)
NOPBT
267,691
241,257
NOPBT Margin
28.06%
22.18%
Operating Taxes
11,546
5,493
Tax Rate
4.31%
2.28%
NOPAT
256,145
235,764
Net income
80,871
-27.48%
111,519
12.11%
Dividends
(42,527)
(19,887)
Dividend yield
1.40%
0.56%
Proceeds from repurchase of equity
(2,989)
(1)
BB yield
0.10%
0.00%
Debt
Debt current
366,929
323,771
Long-term debt
214,250
168,122
Deferred revenue
20,834
22,147
Other long-term liabilities
21,423
3,357
Net debt
59,668
(70,347)
Cash flow
Cash from operating activities
77,782
75,818
CAPEX
Cash from investing activities
(96,697)
Cash from financing activities
56,483
31,544
FCF
163,340
29,187
Balance
Cash
138,331
100,779
Long term investments
383,180
461,462
Excess cash
473,812
507,857
Stockholders' equity
943,902
955,592
Invested Capital
1,232,767
1,127,088
ROIC
21.71%
22.22%
ROCE
15.53%
14.51%
EV
Common stock shares outstanding
244,545
243,809
Price
12.46
-13.95%
14.48
0.36%
Market cap
3,047,032
-13.69%
3,530,356
-0.01%
EV
3,201,465
3,460,008
EBITDA
292,414
266,706
EV/EBITDA
10.95
12.97
Interest
12,930
10,675
Interest/NOPBT
4.83%
4.42%